Associate
Prior to joining Finnegan, Drew conducted research for the Mental Illness, Research, Education and Clinical Center (MIRECC) at the U.S. Department of Veterans Affairs (VA). His work focused on pituitary dysfunction and behavioral symptoms associated with blast-related mild traumatic brain injury. He also collaborated with the Geriatric Research Education and Clinical Center (GRECC) on research related to Alzheimer's disease.
Drew's pro bono activities include representing clients in criminal, landlord-tenant, and asylum proceedings. He has been recognized on the Capital Pro Bono Honor Roll.
Incyte Corp. v. Concert Pharmaceuticals, Inc.
In a rare rehearing proceeding, successfully represented petitioner Incyte in an inter partes review (IPR) challenging the validity of Concert’s patent before the Patent Trial and Appeal Board (PTAB). Continued representation of appellee Incyte before the Federal Circuit and secured a unanimous affirmance of the PTAB’s obviousness determination.
IPR2017-01256, PTAB, Judges Fitzpatrick, Hulse, Yang, Smith, Franklin
19-2011, Fed. Cir., Judges Hughs, Linn, Stark
Teva Pharmaceuticals International GmbH v. Eli Lilly and Company
IPR2022-00738, -00739, -00796, PTAB, Judges Cotta, Wisz, Worth
1:21-cv-10954, D. Mass., Judge Burroughs
SFC Co., Ltd. v. LG Chem, Ltd.
IPR2020-00178, -00182, PTAB, Judges Kalan, Kaiser, Abraham
Blitzsafe Texas, LLC v. BMW et al.
2:17-cv-00418, E.D. Tex., Judge Gilstrap
Eli Lilly and Company v. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
IPR2014-00693, -00752, PTAB, Judges Green, Prats, Snedden
16-1547, Fed. Cir., Judges Bryson, Moore, Newman
AstraZeneca LP v. SigmaPharm Laboratories
1:15-cv-01000, D. Del., Judge Andrews
Articles
In-House Considerations in Advice of Counsel Defense In-House Considerations in Advice of Counsel Defense
May 26, 2021
Westlaw TodayWebinar
Love It AND List It—What’s New with the Orange Book and Hatch-Waxman Litigation Love It AND List It—What’s New with the Orange Book and Hatch-Waxman Litigation
October 16, 2019
Webinar
Articles
Following the Patent Dance Three Years After Sandoz
Following the Patent Dance Three Years After Sandoz
May 28, 2019
Bloomberg LawIP Health Blog
CAFC Affirms Joined IPR Petitioners Have Standing for Appellate Review in Mylan v. RCT CAFC Affirms Joined IPR Petitioners Have Standing for Appellate Review in Mylan v. RCT
February 26, 2019
Prosecution First Blog
Federal Circuit Confirms Joined IPR Petitioners Have Standing for Appellate Review and that Lead-Compound Analysis Is a Fact-Intensive Inquiry Federal Circuit Confirms Joined IPR Petitioners Have Standing for Appellate Review and that Lead-Compound Analysis Is a Fact-Intensive Inquiry
February 5, 2019
Articles
Where Equivalence Isn’t Equivalent: Using 510(k)s in Patent Litigation Where Equivalence Isn’t Equivalent: Using 510(k)s in Patent Litigation
January 3, 2017
Medical Device and Diagnostic IndustryCommentary
Fed. Circ. OKs Boston Drug Developer's Patent Win Fed. Circ. OKs Boston Drug Developer's Patent Win
March 11, 2024
Law360Award/Ranking
54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll 54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll
July 21, 2023
Press Release
46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll 46 Finnegan Attorneys Named to 2021 Capital Pro Bono Honor Roll
June 3, 2022
Press Release
55 Finnegan Attorneys Named to 2020 Capital Pro Bono Honor Roll 55 Finnegan Attorneys Named to 2020 Capital Pro Bono Honor Roll
April 2, 2021
Press Release
62 Finnegan Attorneys Named to 2019 Capital Pro Bono Honor Roll 62 Finnegan Attorneys Named to 2019 Capital Pro Bono Honor Roll
June 8, 2020
Press Release
48 Finnegan Attorneys Named to 2017 Capital Pro Bono Honor Roll 48 Finnegan Attorneys Named to 2017 Capital Pro Bono Honor Roll
February 20, 2018
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.